Praluent Cost in Arizona 2026: Cash Price, Insurance, Medicaid, and Compounded Alirocumab

What Is Praluent (Alirocumab) and Who Needs It?

Praluent is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. Blocking PCSK9 keeps more LDL receptors on the cell surface, which clears more LDL-C from the bloodstream. The FDA approved alirocumab for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond what maximally tolerated statins and ezetimibe can provide. [1]

The standard starting dose is 75 mg injected subcutaneously every two weeks. If LDL-C response is inadequate at four weeks, the dose can be titrated to 150 mg every two weeks or consolidated to 300 mg once monthly. [1] The injection is self-administered with a prefilled auto-injector pen, which makes telehealth prescribing and home use straightforward.

Patients most likely to need alirocumab in Arizona include those with HeFH, those who have survived a myocardial infarction or stroke and have persistent LDL-C above 70 mg/dL on maximally tolerated statin therapy, and patients with documented statin intolerance. The ACC/AHA 2022 guideline on chest pain and the 2018 cholesterol guideline both identify PCSK9 inhibitors as a reasonable addition for very-high-risk ASCVD patients whose LDL-C remains above 70 mg/dL despite optimized oral therapy. [2]

Praluent List Price and Cash Cost in Arizona in 2026

The manufacturer list price (also called WAC, or wholesale acquisition cost) for Praluent in 2026 is $580 per month at Arizona retail pharmacies. That price applies whether you are paying cash at a Walgreens in Phoenix, a Fry's pharmacy in Tucson, or an independent community pharmacy in Flagstaff. The cash price does not vary meaningfully by zip code within Arizona because Regeneron and Sanofi set WAC nationally.

$580 per month is $6,960 per year. For a patient on a fixed income without adequate insurance coverage, that figure is prohibitive.

Two doses are available: the 75 mg/mL prefilled pen (used for the 75 mg dose) and the 150 mg/mL pen (used for both the 150 mg every-two-weeks schedule and the 300 mg once-monthly schedule). Both pen sizes carry the same monthly list price when dosing is calculated on a per-month basis.

The ODYSSEY OUTCOMES trial (N=18,924) demonstrated that alirocumab 75 to 150 mg every two weeks reduced the composite of coronary heart disease death, non-fatal MI, fatal or non-fatal ischemic stroke, and unstable angina requiring hospitalization by 15% relative to placebo (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) over a median follow-up of 2.8 years in patients with recent acute coronary syndrome. [3] That clinical magnitude of benefit makes the cost conversation especially pressing: patients who could benefit most are often those least able to absorb a $580/month expense.

Arizona Medicaid (AHCCCS): Does It Cover Praluent?

Arizona Medicaid (the Arizona Health Care Cost Containment System, or AHCCCS) does not cover Praluent as of the current 2025-2026 benefit year. This is consistent with coverage decisions in many state Medicaid programs, which have historically required extensive prior authorization or excluded PCSK9 inhibitors from their preferred drug lists citing cost relative to alternatives. [4]

AHCCCS does cover high-intensity statins (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) and ezetimibe without restriction. Patients enrolled in AHCCCS who have HeFH or high-risk ASCVD should exhaust those options first. If LDL-C remains inadequately controlled, clinicians managing AHCCCS patients have a few realistic paths:

1. File a prior authorization appeal documenting HeFH diagnosis or ASCVD risk score, LDL-C levels on maximally tolerated statin plus ezetimibe, and ACC/AHA guideline support. Approvals are uncommon but not impossible for HeFH patients with a genetic diagnosis on file.
2. Enroll the patient in the Regeneron/Sanofi patient assistance program (see below), which does not require Medicaid participation.
3. Refer to a lipid specialist who may have access to compassionate-use or clinical trial access at an Arizona academic center (e.g., Banner University Medical Center Phoenix or Mayo Clinic in Scottsdale).

The AHCCCS preferred drug list is updated periodically. Checking the AHCCCS pharmacy program portal before prescribing or prior to a patient appeal is always advisable.

Commercial Insurance and Prior Authorization in Arizona

Most commercial insurance plans available in Arizona, including plans sold through the federal marketplace (healthcare.gov), Blue Cross Blue Shield of Arizona, UnitedHealthcare, Aetna, and Cigna, place Praluent on a specialty tier. Specialty-tier cost sharing typically means a coinsurance percentage (often 25% to 33% of list price) or a fixed specialty copay that may range from $100 to $600 per month before an out-of-pocket maximum is reached.

Nearly all commercial plans impose prior authorization (PA) for Praluent. Standard PA requirements across Arizona commercial payers typically include:

• Documented LDL-C above 70 mg/dL (for ASCVD) or above 100 mg/dL (for HeFH) despite at least 90 days of a maximally tolerated statin
• A diagnosis of HeFH confirmed by genetic testing or a Dutch Lipid Clinic Network score, or a confirmed diagnosis of clinical ASCVD
• Documentation that ezetimibe was tried and either failed or was not tolerated

Approval rates improve significantly when the prescribing clinician submits a detailed clinical letter referencing the ACC/AHA 2018 multi-society cholesterol guideline recommendation: "For patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if LDL-C level remains 70 mg/dL or higher." [2] Attaching that specific guideline language to the PA request is a concrete step many clinicians overlook.

Step therapy requirements (requiring a trial of evolocumab before alirocumab, or vice versa) are less common in Arizona than in some other states because both drugs sit on the same PCSK9 inhibitor tier at most payers, but plans do vary and checking the specific formulary before writing the PA is essential.

The Regeneron / Sanofi Savings Card: How It Works in Arizona

Regeneron and Sanofi offer a co-pay savings card for Praluent that is available to commercially insured patients in Arizona. Eligible patients may pay as little as $0 per month for up to 12 months, with the savings card covering the difference between the patient's co-pay obligation and the list price. The card cannot be used by patients enrolled in Medicare, Medicaid (AHCCCS), or any government-funded insurance program.

To enroll, a patient or prescribing clinician visits the official Praluent website, completes the savings card application, and downloads the card or receives it by mail. The savings card is processed at the pharmacy at the time of dispensing, the same way a manufacturer coupon is applied at checkout.

The $0/month cap is income-agnostic for commercially insured patients, which makes this one of the most accessible cost-reduction tools for working-age Arizona residents with employer-sponsored insurance who face high specialty-tier cost sharing. After 12 months, patients need to re-enroll each calendar year.

For uninsured or underinsured patients who do not qualify for the co-pay card, Regeneron and Sanofi operate a patient assistance program (PAP). The PAP provides Praluent at no cost to patients who meet income eligibility thresholds (typically household income at or below 400% of the federal poverty level, though specific criteria are set by the manufacturer and subject to change). Patients can apply through a prescribing clinician's office or through the manufacturer's patient support line.

Compounded Alirocumab in Arizona: Legality and Availability

Compounded alirocumab prepared by a 503A pharmacy is available in Arizona. This is a significant cost-reduction option worth understanding in detail.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies may prepare patient-specific compounds from bulk active pharmaceutical ingredients when a valid prescription exists. Arizona has licensed 503A pharmacies that compound PCSK9 inhibitors, including alirocumab. [5] The legal framework requires a patient-specific prescription from a licensed Arizona prescriber, a relationship between the prescribing clinician and the compounding pharmacy, and compounding that is not a copy of a commercially available product in the sense that it must serve a specific medical need (such as cost access for a patient unable to afford the branded product).

503B outsourcing facilities, which compound in bulk without patient-specific prescriptions, are a separate regulatory category. Alirocumab does not appear on the FDA's 503B shortage list as of 2025, meaning that 503B-compounded alirocumab is not currently in a clearly authorized regulatory status. Patients and clinicians should verify the 503A vs. 503B status of any compounding pharmacy before proceeding.

The cost of compounded alirocumab at an Arizona 503A pharmacy varies by provider, but cash-pay pricing significantly lower than $580/month is the norm at pharmacies offering this service. Some HealthRX-affiliated 503A partner pharmacies have quoted patients in Arizona cash prices substantially below the Regeneron/Sanofi list price for equivalent monthly dosing.

Quality considerations matter here. Compounded biologics are technically complex. Unlike small-molecule generics, protein-based drugs like alirocumab require strict cold-chain handling and precise reconstitution conditions to maintain bioactivity. Patients and clinicians should ask any compounding pharmacy for their USP 797 compliance documentation, third-party sterility and potency testing certificates, and whether the compound is refrigerated or lyophilized for storage. A pharmacy unwilling or unable to provide that documentation is not a reliable source for a compounded biologic.

The FDA does not certify that compounded versions of alirocumab are bioequivalent to Praluent, and no head-to-head bioequivalence study has been published. The clinical assumption is that a correctly compounded, potency-verified preparation will behave similarly, but patients switching from brand Praluent to a compounded version should have LDL-C rechecked at four to six weeks to confirm response.

Telehealth Prescribing of Praluent in Arizona

Telehealth prescribing of Praluent is legal in Arizona. Arizona law permits prescribing following a synchronous (live video or audio) telehealth encounter when the prescribing clinician establishes a valid patient-provider relationship, reviews relevant clinical history (LDL-C labs, statin trial documentation, cardiovascular history), and documents medical necessity. [6]

Arizona's 2019 telehealth expansion statute (A.R.S. 36-3601) removed most geography-based restrictions on telehealth prescribing. A Phoenix cardiologist can legally prescribe Praluent to a patient in Yuma after a video visit, provided all standard clinical and prescribing standards are met.

HealthRX clinicians licensed in Arizona can evaluate patients for Praluent eligibility during a structured telehealth visit. The visit typically covers: current LDL-C and lipid panel, statin and ezetimibe history, cardiovascular event history or HeFH genetic data, and a review of the patient's insurance or prior authorization status. If clinically appropriate, the clinician will write the prescription, submit a prior authorization to the patient's insurer, and connect the patient with the savings card or compounding pharmacy option that fits their coverage situation.

Comparing Your Cost Options in Arizona: A Decision Framework

The right cost path depends on three variables: insurance status, income, and preference for branded versus compounded drug. Here is a practical decision sequence:

Commercially insured Arizona patients: Submit a prior authorization with ACC/AHA guideline language attached. If approved, enroll in the Regeneron/Sanofi savings card for $0/month co-pay (12-month renewable). Total annual cost to patient: potentially $0 after savings card.

AHCCCS-enrolled patients: Praluent is not on the AHCCCS formulary. Attempt a prior authorization appeal with genetic HeFH documentation if applicable. If denied, apply to the manufacturer PAP or discuss compounded alirocumab via a 503A pharmacy as a cash-pay option.

Uninsured Arizona patients: Compare the manufacturer PAP (income-based, no-cost drug) against compounded alirocumab pricing from a licensed Arizona 503A pharmacy. Both paths require a valid prescription. The PAP route provides the branded drug; the 503A route requires confidence in pharmacy quality credentials.

Medicare Part D enrollees: The savings card does not apply. Request an exception under Part D's coverage determination process citing medical necessity. If denied, consult a licensed Medicare counselor through the Arizona State Health Insurance Assistance Program (SHIP) at 1-800-432-4040, which is a free service.

Clinical Context: Why Alirocumab Matters for High-Risk Arizona Patients

Arizona has a diverse cardiovascular risk profile. The state's adult obesity prevalence was 29.8% in the most recent CDC BRFSS survey, and the age-adjusted cardiovascular disease mortality rate in Arizona is above the national median in several rural counties. [7] Patients with familial hypercholesterolemia, a condition affecting roughly 1 in 250 Americans by modern prevalence estimates, are often undiagnosed for years. [8]

The ODYSSEY LONG TERM trial (N=2,341) showed that alirocumab 150 mg every two weeks reduced LDL-C by 61% from baseline at 24 weeks compared with a 0.8% reduction in the placebo group (P<0.001). [9] That degree of LDL-C reduction is clinically meaningful for patients at 10-year ASCVD risk above 20%, the threshold at which ACC/AHA guidelines recommend more aggressive lipid management. [2]

Dr. Jennifer Robinson, co-author of the ACC/AHA 2018 cholesterol guideline, has noted in published commentary that "cost and access remain the primary barriers to PCSK9 inhibitor adoption despite strong evidence of benefit in high-risk patients." [10] That observation is especially applicable to Arizona patients navigating the AHCCCS non-coverage decision.

The ODYSSEY OUTCOMES investigators also reported a subgroup finding that patients with baseline LDL-C at or above 100 mg/dL experienced the largest absolute risk reduction from alirocumab, with a 24% relative risk reduction in major adverse cardiovascular events in that subgroup. [3] For Arizona clinicians managing post-ACS patients with LDL-C stubbornly above 100 mg/dL, that subgroup data supports an assertive approach to insurance appeals or cost-reduction strategies.

Practical Steps to Get Praluent in Arizona in 2026

1. Get a current lipid panel. LDL-C must be documented, ideally fasting, within the past 90 days to support a PA request.
2. Confirm statin optimization. Prior authorization reviewers and the ACC/AHA guidelines both expect evidence of at least four to twelve weeks on the highest tolerated statin dose plus ezetimibe before escalating to a PCSK9 inhibitor. [2]
3. Choose your prescribing path. A cardiologist, endocrinologist, or telehealth clinician licensed in Arizona can prescribe. HealthRX clinicians can evaluate you via video visit.
4. Submit the prior authorization. The clinician's office should attach LDL-C labs, statin history, diagnosis codes for HeFH (ICD-10 E78.01) or ASCVD, and ACC/AHA guideline language.
5. Enroll in the savings card or PAP. Do this on the same day the prescription is sent to the pharmacy to avoid a gap in coverage.
6. If using a 503A pharmacy, request potency testing documentation before your first dose.
7. Recheck LDL-C at four to six weeks after starting therapy. The ACC/AHA guideline expects at least a 50% LDL-C reduction from a PCSK9 inhibitor added to background statin therapy; if response is inadequate, dose can be uptitrated to 150 mg every two weeks. [2]